Browsing by Author "Marques, C."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Patterns of Play in the Counterattack of Elite Football Teams - A Mixed Method ApproachPublication . Sarmento, H.; Anguera, MT.; Pereira, A.; Marques, C.; Leitão, J.This study aimed to detect and analyse regular patterns of play in football teams during their offensive phase, through the combination of the sequential analysis technique and semi-structured interviews of experienced first League Portuguese coaches. The sample included 36 games (12 per team) of the F.C. Barcelona, Internazionalle Milano, and Manchester United teams that were analysed through sequential analysis with the software SDIS-GSEQ. Based on the detected patterns, semi-structured interviews were carried out with 8 expert high-performance football coaches. Data were analysed through the content analysis technique using the software Nvivo 9. The detected patterns of play revealed specific characteristics of different philosophies of play. Through the performed content analysis we could observe that coaches interpreting play patterns mainly based their opinions on tactical-strategic and tactical-technical aspects, and on the characteristics of the players on their team. On the other hand, consideration was given to three of the main evolutionary trends of play/soccer practice, which focus on the development of exercises that cover: i) the connection between the four play moments (offensive/defensive organization and transitions); ii) the pre-programmed ball possession recovery; iii) the execution of set pieces.
- Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effectsPublication . Marques, C.; Mega, C.; Gonçalves, A.; Rodrigues-Santos, P.; Vala, Helena; Teixeira-Lemos, E.; Teixeira, F.; Fontes-Ribeiro, C.; Reis, F.; Fernandes, R.Objective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat. Methods: ZDF rats (aged 20 weeks) were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia, HbA1c, urea and creatinine levels were monitored. Kidney glomerular and tubulointerstitial lesions were assessed using a semiquantitative rating. Kidney mRNA and/or protein content of DPP-IV, GLP-1, TNF-α, IL-1β, BAX, Bcl-2 and Bid were evaluated by RT-PCR and/or WB. Protein distribution was evaluated by immunohistochemistry. Results: Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c, and prevented the diabetes-induced increase in DPP-IV levels and decrease in GLP-1 levels. Sitagliptin ameliorated diabetes-induced glomerular atrophy and IFTA, and the increased urea levels. Sitagliptin decreased kidney IL-1β and TNF-α, and prevented the increase of BAX/Bcl-2 ratio and Bid protein levels, which indicates protective effects against inflammation and pro-apoptotic state in the kidney of diabetic rats, respectively. Conclusion: Sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and anti-apoptotic properties.